Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $4.17 earnings per share for the quarter, topping the consensus estimate of $2.67 by $1.50. The business earned $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company's revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.82 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

27 equities research analysts have issued 1-year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $345.00 to $605.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $490.17 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

• 1. Canaccord Genuity analysts commented, "Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible." (10/16/2017)
• 2. According to Zacks Investment Research, "With Eylea accounting for the majority of revenues at Regeneron, Regeneron relies heavily on the drug for growth. In the U.S., the company is witnessing increased competitor discounts and rebates. Sub-par performance of the product will hurt the stock as Eylea is Regeneron’s key growth driver. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. However, sales of Praluent have failed to impress as the drug is facing significant payer utilization management restrictions in the U.S. and limited market access in Europe, which is resulting in a low volume of prescriptions being dispensed. Nevertheless, the approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line. Shares have outperformed the industry so far in 2017." (10/10/2017)
• 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
• 4. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
• 5. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)

Some companies that are related to Regeneron Pharmaceuticals include Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), BIOVERATIV INC (BIVV), bluebird bio (BLUE), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO) and Aerie Pharmaceuticals (AERI).

Regeneron Pharmaceuticals' management team includes the folowing people:

• P. Roy Vagelos M.D., Chairman of the Board
• Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
• Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
• Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
• Neil Stahl Ph.D., Executive Vice President - Research and Development
• Robert J. Terifay, Executive Vice President - Commercial
• Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
• Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
• Peter Powchik M.D., Senior Vice President - Clinical Development
• George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.12%), Nationwide Fund Advisors (0.07%), State Treasurer State of Michigan (0.02%), APG Asset Management N.V. (0.02%), Shell Asset Management Co. (0.01%) and BB&T Corp (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, State Treasurer State of Michigan, Sumitomo Life Insurance Co., Ingalls & Snyder LLC and Eqis Capital Management Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Northpointe Capital LLC, Shell Asset Management Co., APG Asset Management N.V., Meeder Asset Management Inc., BB&T Corp, Prentiss Smith & Co. Inc. and Winslow Evans & Crocker Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $432.76.